Molecular  ||| S:0 E:10 ||| JJ
targeting  ||| S:10 E:20 ||| NN
and  ||| S:20 E:24 ||| CC
gene  ||| S:24 E:29 ||| NN
delivery  ||| S:29 E:38 ||| NN
in  ||| S:38 E:41 ||| IN
bladder  ||| S:41 E:49 ||| JJ
cancer  ||| S:49 E:56 ||| NN
therapy  ||| S:56 E:64 ||| NN
Urothelial  ||| S:64 E:75 ||| NNP
carcinoma  ||| S:75 E:85 ||| NN
of  ||| S:85 E:88 ||| IN
the  ||| S:88 E:92 ||| DT
bladder  ||| S:92 E:100 ||| NN
is  ||| S:100 E:103 ||| VBZ
the  ||| S:103 E:107 ||| DT
second  ||| S:107 E:114 ||| JJ
most  ||| S:114 E:119 ||| RBS
common  ||| S:119 E:126 ||| JJ
genitourinary  ||| S:126 E:140 ||| JJ
malignancy  ||| S:140 E:151 ||| NN
and  ||| S:151 E:155 ||| CC
the  ||| S:155 E:159 ||| DT
second  ||| S:159 E:166 ||| JJ
most  ||| S:166 E:171 ||| RBS
common  ||| S:171 E:178 ||| JJ
cause  ||| S:178 E:184 ||| NN
of  ||| S:184 E:187 ||| IN
genitourinary  ||| S:187 E:201 ||| JJ
cancer-related  ||| S:201 E:216 ||| JJ
deaths  ||| S:216 E:223 ||| NNS
with  ||| S:223 E:228 ||| IN
a  ||| S:228 E:230 ||| DT
worldwide  ||| S:230 E:240 ||| JJ
estimate  ||| S:240 E:249 ||| NN
of  ||| S:249 E:252 ||| IN
about  ||| S:252 E:258 ||| IN
300,000  ||| S:258 E:266 ||| CD
new  ||| S:266 E:270 ||| JJ
cases  ||| S:270 E:276 ||| NNS
diagnosed  ||| S:276 E:286 ||| VBD
every  ||| S:286 E:292 ||| DT
year ||| S:292 E:296 ||| NN
.  ||| S:296 E:298 ||| .
A  ||| S:298 E:300 ||| DT
significant  ||| S:300 E:312 ||| JJ
problem  ||| S:312 E:320 ||| NN
in  ||| S:320 E:323 ||| IN
this  ||| S:323 E:328 ||| DT
type  ||| S:328 E:333 ||| NN
of  ||| S:333 E:336 ||| IN
cancer  ||| S:336 E:343 ||| NN
is  ||| S:343 E:346 ||| VBZ
the  ||| S:346 E:350 ||| DT
high  ||| S:350 E:355 ||| JJ
recurrence  ||| S:355 E:366 ||| NN
rate  ||| S:366 E:371 ||| NN
of  ||| S:371 E:374 ||| IN
non-invasive  ||| S:374 E:387 ||| JJ
primary  ||| S:387 E:395 ||| JJ
tumors ||| S:395 E:401 ||| NNS
,  ||| S:401 E:403 ||| ,
leading  ||| S:403 E:411 ||| VBG
to  ||| S:411 E:414 ||| TO
a  ||| S:414 E:416 ||| DT
high  ||| S:416 E:421 ||| JJ
percentage  ||| S:421 E:432 ||| NN
of  ||| S:432 E:435 ||| IN
tumor  ||| S:435 E:441 ||| NN
progression  ||| S:441 E:453 ||| NNS
and  ||| S:453 E:457 ||| CC
to  ||| S:457 E:460 ||| TO
a  ||| S:460 E:462 ||| DT
very  ||| S:462 E:467 ||| RB
poor  ||| S:467 E:472 ||| JJ
5-year  ||| S:472 E:479 ||| CD
survival  ||| S:479 E:488 ||| NN
rate ||| S:488 E:492 ||| NN
.  ||| S:492 E:494 ||| .
Targeted  ||| S:494 E:503 ||| NNP
and  ||| S:503 E:507 ||| CC
gene  ||| S:507 E:512 ||| NN
therapy  ||| S:512 E:520 ||| NNS
are  ||| S:520 E:524 ||| VBP
currently  ||| S:524 E:534 ||| RB
the  ||| S:534 E:538 ||| DT
two  ||| S:538 E:542 ||| CD
major  ||| S:542 E:548 ||| JJ
efforts  ||| S:548 E:556 ||| NNS
in  ||| S:556 E:559 ||| IN
cancer  ||| S:559 E:566 ||| NN
treatment ||| S:566 E:575 ||| NN
.  ||| S:575 E:577 ||| .
Targeted  ||| S:577 E:586 ||| JJ
therapy  ||| S:586 E:594 ||| NN
refers  ||| S:594 E:601 ||| VBZ
to  ||| S:601 E:604 ||| TO
strategies  ||| S:604 E:615 ||| NNS
against  ||| S:615 E:623 ||| IN
specific  ||| S:623 E:632 ||| JJ
cellular  ||| S:632 E:641 ||| JJ
molecules  ||| S:641 E:651 ||| NNS
deregulated  ||| S:651 E:663 ||| VBN
in  ||| S:663 E:666 ||| IN
tumors ||| S:666 E:672 ||| NNS
,  ||| S:672 E:674 ||| ,
whereas  ||| S:674 E:682 ||| IN
gene  ||| S:682 E:687 ||| NN
therapy  ||| S:687 E:695 ||| NN
focuses  ||| S:695 E:703 ||| VBZ
on  ||| S:703 E:706 ||| IN
the  ||| S:706 E:710 ||| DT
genetic  ||| S:710 E:718 ||| JJ
modification  ||| S:718 E:731 ||| NN
of  ||| S:731 E:734 ||| IN
tumor  ||| S:734 E:740 ||| NN
cells ||| S:740 E:745 ||| NNS
,  ||| S:745 E:747 ||| ,
mainly  ||| S:747 E:754 ||| RB
for  ||| S:754 E:758 ||| IN
correcting  ||| S:758 E:769 ||| JJ
gene  ||| S:769 E:774 ||| NN
defects ||| S:774 E:781 ||| NNS
,  ||| S:781 E:783 ||| ,
inducing  ||| S:783 E:792 ||| VBG
selective  ||| S:792 E:802 ||| JJ
tumor  ||| S:802 E:808 ||| NN
cell  ||| S:808 E:813 ||| NN
death  ||| S:813 E:819 ||| NN
or  ||| S:819 E:822 ||| CC
modulating  ||| S:822 E:833 ||| JJ
host ||| S:833 E:837 ||| NN
's  ||| S:837 E:840 ||| POS
immune  ||| S:840 E:847 ||| JJ
response ||| S:847 E:855 ||| NN
.  ||| S:855 E:857 ||| .
Recent  ||| S:857 E:864 ||| JJ
advances  ||| S:864 E:873 ||| NNS
in  ||| S:873 E:876 ||| IN
our  ||| S:876 E:880 ||| PRP$
understanding  ||| S:880 E:894 ||| NN
of  ||| S:894 E:897 ||| IN
the  ||| S:897 E:901 ||| DT
pathogenesis  ||| S:901 E:914 ||| NN
of  ||| S:914 E:917 ||| IN
bladder  ||| S:917 E:925 ||| JJ
cancer  ||| S:925 E:932 ||| NN
at  ||| S:932 E:935 ||| IN
the  ||| S:935 E:939 ||| DT
molecular  ||| S:939 E:949 ||| JJ
level  ||| S:949 E:955 ||| NN
have  ||| S:955 E:960 ||| VBP
provided  ||| S:960 E:969 ||| VBN
a  ||| S:969 E:971 ||| DT
significant  ||| S:971 E:983 ||| JJ
number  ||| S:983 E:990 ||| NN
of  ||| S:990 E:993 ||| IN
cellular  ||| S:993 E:1002 ||| JJ
targets  ||| S:1002 E:1010 ||| NNS
for  ||| S:1010 E:1014 ||| IN
therapy  ||| S:1014 E:1022 ||| NN
and  ||| S:1022 E:1026 ||| CC
have  ||| S:1026 E:1031 ||| VBP
shown  ||| S:1031 E:1037 ||| VBN
the  ||| S:1037 E:1041 ||| DT
importance  ||| S:1041 E:1052 ||| NN
of  ||| S:1052 E:1055 ||| IN
individualized  ||| S:1055 E:1070 ||| JJ
therapy  ||| S:1070 E:1078 ||| NN
according  ||| S:1078 E:1088 ||| VBG
to  ||| S:1088 E:1091 ||| TO
the  ||| S:1091 E:1095 ||| DT
molecular  ||| S:1095 E:1105 ||| JJ
profile  ||| S:1105 E:1113 ||| NN
exhibited  ||| S:1113 E:1123 ||| NN
by  ||| S:1123 E:1126 ||| IN
the  ||| S:1126 E:1130 ||| DT
tumor  ||| S:1130 E:1136 ||| NN
cells ||| S:1136 E:1141 ||| NNS
.  ||| S:1141 E:1143 ||| .
While  ||| S:1143 E:1149 ||| IN
the  ||| S:1149 E:1153 ||| DT
major  ||| S:1153 E:1159 ||| JJ
problems  ||| S:1159 E:1168 ||| NNS
of  ||| S:1168 E:1171 ||| IN
both  ||| S:1171 E:1176 ||| DT
targeted  ||| S:1176 E:1185 ||| JJ
and  ||| S:1185 E:1189 ||| CC
gene  ||| S:1189 E:1194 ||| NN
therapy  ||| S:1194 E:1202 ||| NNS
are  ||| S:1202 E:1206 ||| VBP
far  ||| S:1206 E:1210 ||| RB
from  ||| S:1210 E:1215 ||| IN
being  ||| S:1215 E:1221 ||| VBG
solved  ||| S:1221 E:1228 ||| VBN
yet ||| S:1228 E:1231 ||| RB
,  ||| S:1231 E:1233 ||| ,
both  ||| S:1233 E:1238 ||| DT
lines  ||| S:1238 E:1244 ||| NNS
of  ||| S:1244 E:1247 ||| IN
cancer  ||| S:1247 E:1254 ||| NN
therapy  ||| S:1254 E:1262 ||| NNS
hold  ||| S:1262 E:1267 ||| VBP
promising  ||| S:1267 E:1277 ||| VBG
results ||| S:1277 E:1284 ||| NNS
.  ||| S:1284 E:1286 ||| .
This  ||| S:1286 E:1291 ||| DT
article  ||| S:1291 E:1299 ||| NN
aims  ||| S:1299 E:1304 ||| VBZ
at  ||| S:1304 E:1307 ||| IN
providing  ||| S:1307 E:1317 ||| VBG
a  ||| S:1317 E:1319 ||| DT
brief  ||| S:1319 E:1325 ||| JJ
general  ||| S:1325 E:1333 ||| JJ
overview  ||| S:1333 E:1342 ||| NN
of  ||| S:1342 E:1345 ||| IN
this  ||| S:1345 E:1350 ||| DT
broad  ||| S:1350 E:1356 ||| JJ
subject ||| S:1356 E:1363 ||| NN
.  ||| S:1363 E:1365 ||| .
